Orchard Therapeutics plc (ORTX)
| Previous close | 1.9000 |
| Open | 1.9000 |
| Bid | 1.9600 x 1100 |
| Ask | 1.9700 x 2200 |
| Day's range | 1.8800 - 1.9700 |
| 52-week range | 1.8500 - 9.0800 |
| Volume | 174,028 |
| Avg. volume | 932,649 |
| Market cap | 242.587M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3200 |
| Earnings date | 04 Aug 2021 - 09 Aug 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 12.89 |
- Globe Newswire
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress
Nine accepted abstracts demonstrate broad potential of the company’s HSC gene therapy approach to treat severe neurodegenerative diseases and immunological disordersBOSTON and LONDON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of nine abstracts at the upcoming European Society of Gene & Cell Therapy Congress (ESGCT) taking place virtually from October 19-22. Clinical and pre-clinical data from across the com
- Globe Newswire
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event
Novel Discovery Research in HSC-generated Antigen-specific Regulatory T Cells Disclosed HSC Gene Therapy Also Provides Advantages for Delivery of Monoclonal Antibodies New Applications Present Opportunities for Future Partnerships BOSTON and LONDON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today will present on the company’s discovery and research efforts in hematopoietic stem cell (HSC) gene therapy, including an update on the OTL-104
- Globe Newswire
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
Gene therapy experts Fulvio Mavilio, Ph.D., and Nicoletta Loggia, Ph.D., join as chief scientific officer and chief technical officer, respectively Neuroscience and rare disease leader Leslie Meltzer, Ph.D., promoted to chief medical officer Appointments reinforce company’s strategic focus on innovation in the areas of discovery, clinical development and manufacturing BOSTON and LONDON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today an
